CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
October 23 2007 - 4:01PM
PR Newswire (US)
PALO ALTO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) announced today that multiple
abstracts, including data from a prospectively identified analysis
of patients with diabetes in the MERLIN TIMI-36 study, have been
accepted for presentation at the American Heart Association (AHA)
Scientific Sessions 2007, which will be held in Orlando, FL on
November 4 - 7, 2007. Ranexa(R) (ranolazine extended-release
tablets): Prospective Evaluation of the Prognostic Implications of
Low Level Elevation of Cardiac Troponin Using a New
Highly-sensitive Assay for Cardiac Troponin I: Results from the
MERLIN TIMI-36 Trial; Oral abstract, Monday, November 5, 2007, 9:30
a.m. EST B-type Natriuretic Peptide and the Effect of Ranolazine in
Patients with Non- ST Elevation Acute Coronary Syndromes in the
MERLIN TIMI-36 Trial; Oral abstract, Monday, November 5, 2007,
10:00 a.m. EST Anti-Ischemic Effects of Ranolazine in Women:
Results from the Randomized, Placebo-controlled MERLIN TIMI-36
Trial; Oral abstract, Tuesday, November 6, 2007, 10:00 a.m. EST
Effect of Ranolazine on Hemoglobin A1c in the MERLIN TIMI-36
Randomized Controlled Trial; Oral abstract, Tuesday, November 6,
2007, 11:00 a.m. EST Baseline Clinical Risk and Recurrent Ischemia
as Detected on Continuous ECG (CECG) Monitoring in Patients with
non-ST-Elevation Acute Coronary Syndrome in the MERLIN TIMI-36
Trial; Poster, Wednesday, November 7, 2007, 9:30 - 11:00 a.m. EST
Tecadenoson Ventricular Rate Control Using the Adenosine Receptor
Agonist CVT 510 in the Goat Model of Atrial Fibrillation: Efficacy
During Exercise and Synergistic Effects with Metoprolol; Oral
abstract, Tuesday, November 6, 2007, 4:15 p.m. EST Additional
information regarding the AHA Scientific Sessions 2007 can be
accessed at http://scientificsessions.org/. About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology
to the discovery, development and commercialization of novel, small
molecule drugs for the treatment of cardiovascular diseases. CV
Therapeutics' approved product, Ranexa(R) (ranolazine
extended-release tablets), is indicated for the treatment of
chronic angina in patients who have not achieved an adequate
response with other antianginal drugs, and should be used in
combination with amlodipine, beta-blockers or nitrates. CV
Therapeutics' clinical and preclinical drug development candidates
and programs include regadenoson, which is being developed for
potential use as a pharmacologic stress agent in myocardial
perfusion imaging studies, and CVT- 6883, which is being developed
as a potential treatment for cardiopulmonary diseases. Regadenoson
and CVT-6883 have not been determined by any regulatory authorities
to be safe or effective in humans for any use. Except for the
historical information contained herein, the matters set forth in
this press release are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially, including operating losses and fluctuations in
operating results; capital requirements; regulatory review and
approval of our products; special protocol assessment agreement;
the conduct and timing of clinical trials; commercialization of
products; market acceptance of products; product labeling;
concentrated customer base; and other risks detailed from time to
time in CV Therapeutics' SEC reports, including its Quarterly
Report on Form 10-Q for the quarter ended June 30, 2007. CV
Therapeutics disclaims any intent or obligation to update these
forward-looking statements. DATASOURCE: CV Therapeutics, Inc.
CONTACT: John Bluth, Executive Director, Corporate Communications
& Investor Relations of CV Therapeutics, Inc., +1-650-384-8850
Web site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024